Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. #lymphoma #lymsm https://t.co/yKCIJ6X2EC
RT @Berninini: Nice study! This fits with our recently published experience as well - no increased risk of proven/probable IMI with mica. W…
RT @GermHunterMD: #Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy In a 1-centre, 1-arm, prospective…
RT @GermHunterMD: #Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy In a 1-centre, 1-arm, prospective…
RT @Berninini: Nice study! This fits with our recently published experience as well - no increased risk of proven/probable IMI with mica. W…
RT @GermHunterMD: #Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy In a 1-centre, 1-arm, prospective…
RT @GermHunterMD: #Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy In a 1-centre, 1-arm, prospective…
Nice study! This fits with our recently published experience as well - no increased risk of proven/probable IMI with mica. Will become more important as we use more TKIs upfront in AML. https://t.co/Lx5pgWURdF
#Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy In a 1-centre, 1-arm, prospective study, 3/65 (4.6%) pts w/ acute leukemia on mica ppx had breakthru IFI (2/32 [6.3%] w/ AML, vs 2/39 [5.1%] historical AML pts on posa)